Leerink raises Nanobiotix price target on cancer drug data

Created at 4 Jun · 09:12 UTC2 sources↑ Market-relevant2 events

IN SHORT

Leerink has raised its stock price target for Nanobiotix, citing new data for its cancer drug and positive R&D pipeline developments.

Who's Involved

Leerink

Investment bank that raised Nanobiotix's stock price target

Nanobiotix

Biotechnology company with a cancer drug in development

Key facts

Leerink raised Nanobiotix's stock price target.
The target increase is based on new data for Nanobiotix's cancer drug.
The adjustment reflects positive R&D pipeline developments.

Investment bank Leerink has raised its stock price target for Nanobiotix. This decision comes after the company released new data concerning its cancer drug. The increased target signifies Leerink's positive assessment of Nanobiotix's research and development progress and its pipeline.

↳ Why This Matters

Analyst rating changes can influence investor sentiment and stock prices, particularly for smaller biotechnology companies relying on pipeline developments.

FREQUENTLY ASKED

Leerink raised its stock price target for Nanobiotix.

The increase was based on new data for Nanobiotix's cancer drug and reflects positive developments in its R&D pipeline.

Get the newsletter.

Pick the topics you actually care about. We'll email when there's news worth your time, on the cadence you choose. Cancel any time from your account.

Cadence

CME Headlines

Key facts

Leerink raised Nanobiotix's stock price target.

The target increase is based on new data for Nanobiotix's cancer drug.

The adjustment reflects positive R&D pipeline developments.

Leerink raises Nanobiotix price target on cancer drug data

PiQ Daily

Key facts

Get the newsletter.

Leerink raises Nanobiotix price target on cancer drug data

PiQ Daily

Key facts

Get the newsletter.